Imagine being a store owner who sells machines without knowing exactly what they do. Some of your products could help farmers grow more nutritious crops while a few others could spread disease among thousands of people. Part of your inventory would do nothing at all.

This is the quandary facing many biotech companies that specialize in synthesizing or printing DNA. By selling genes, they have empowered synthetic biologists seeking to genetically engineer organisms capable of fighting disease or producing industrial materials.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy